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This paper describes the use of a layer-by-layer nanocoating technique for the encapsulation of insulin-producing
pancreatic -cell spheroids (pseudoislets) within chitosan/alginate multilayers. We used pseudoislets self-organized
from a population of the insulinoma cell line MIN6, derived from a transgenic mouse expressing the large T-antigen
of SV40 in pancreatic -cells, as an experimental model for the study of cell nanoencapsulation. The maintenance
of spheroid morphology and retention of cell viability and metabolic functionality was demonstrated postencap-
sulation. By depositing an additional protein-repelling phosphorylcholine-modified chondroitin-4-sulfate layer,
the coatings were found to shield effectively access of large molecules of the immune systems to the antigen-
presenting cell surfaces. Transmission electron microscopy analysis of the encapsulated pseudoislets revealed
that the coating did not damage the cell structure. In addition, nanoencapsulation permits the cells to respond to
changes in extracellular glucose and other insulin secretagogues by releasing insulin with a profile similar to that
of nonencapsulated cells. These results suggest that this nanofilm encapsulation technique has the characteristics
required for the efficient transplantation of cellular engineered -cells as a cell replacement therapy for type 1
diabetes. This encapsulation method is general in scope and has implications for use in a variety of cellular
therapeutics employing engineered tissues from cells generated in vitro from various sources, including those
using genetic and cellular engineering techniques.
Introduction
Encapsulation of living cells such as insulin-producing
pancreatic islet cells with semipermeable membranes provides
added possibilities for complex cell-based therapies, promising
cell transplantation without the need for immune-suppressive
therapy.1 Improved encapsulation technology of islet cells is
urgently needed for the treatment of type 1 diabetes.2 Traditional
immune-isolating strategies involving the use of micro- and
macro-type encapsulation approaches have used a relatively
large size of capsule which imposes consequential limitations
on access of cells to oxygen and nutrients and produces
transplant volumes unsuitable for infusion into clinically
preferred sites such as the portal bloodstream.3,4 Recently, in
an effort to reduce the size and void volume of the immune-
isolation devices, several studies have introduced low transplant-
volume encapsulation strategies, which include conformal
microcoating,5 surface polyethylene glycol (PEG) functional-
ization,6 and more recently multilayer nanocoating.7-10 These
approaches promise optimal transplant volumes for intraportal
islet transplantation and are key strategies toward improved long-
term graft survival of encapsulated islet cells.
The use of nanometer-thin film buildup approaches via
electrostatic layer-by-layer (LBL) assembly is particularly
attractive for cell encapsulation and in vivo applications,11 due
to its mild conditions, nanoscale precision, and the ability to
generate films with controlled thickness and surface character-
istics.12 Several previous studies have already demonstrated the
feasibility of multilayer nanoencapsulation of human pancreatic
islets using the LBL approach.7,8 From the point of view of
clinical application, however, these protocols for the encapsu-
lated human islet transplantation suffer from primary tissue-
sourcing constraints for the following reasons. An adult human
pancreas contains approximately 106 islets (∼2 × 109 -cells),
but these comprise only a minor part of total pancreatic tissue
(2-3%). So islets for transplantation must be isolated from
whole pancreas by enzymatic digestion, which is an inefficient
process. To ensure a successful outcome, islet transplantation
protocols should be able to replace up to 106 primary human
islets per recipient, so a single transplantation may require islets
from up to four donor pancreases. At present, the only suitable
source of human islets for clinical use is from pancreases of
heart-beating, brain-dead donors. This type of organ donor is
rare, so current transplantation protocols using human islets are
unlikely to make a widespread therapeutic impact on diabetes.13
Recent trends in transplantation therapy have put strong
emphasis on alternative approaches to generating functionally
competent, insulin-secreting -cells as substitutes for donor
islets, for example, by using genetic and cellular engineering
techniques to produce a source of islet cells.14-16 A number of
insulin-expressing cells have been derived from insulin-secreting
cell lines, non--cells engineered by gene therapy, -cells from
other species, and cells derived from tissue and embryonic stem
cells.13 However, a major obstacle for the clinical use of such
engineered cells is their possible immunogenicity, and thus,
immunoisolation appears to be a practical approach to trans-
plantation of these cells. However, there is no suitable meth-
odology available for encapsulating cells in the form of in vitro
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engineered artificial tissues or organs using the clinically
preferred low transplant-volume nanoencapsulation technologies.
The insulinoma cell line MIN6 is a convenient insulin-
producing cell source that has been traditionally used as an
experimental model for studying the mechanism of glucose-
stimulated insulin secretion in pancreatic -cells.17 MIN6 cells
have been previously used in a microencapsulation system18,19
and shown to reverse diabetes in rats.19 Dispersed single MIN6
cells are, however, unsuitable for encapsulation in a nanocoating
with a low void volume, because they may rapidly undergo
apoptosis due to lack of cell-to-cell interactions that are needed
also for maintaining normal functions including glucose-
dependent secretion of insulin in MIN6 cells.20 Nevertheless,
it is well-known that individual MIN6 cells dispersed into cell
suspensions can spontaneously reaggregate in vitro into three-
dimensional islet-like structures (“pseudoislets”) that support
cell viability and restore some of the function lost on tissue
dispersal.21,22 In accordance with this, in the present study we
have prepared pseudoislet structures by taking advantage of a
self-organization process of the individual MIN6 -cells in
culture and then used the LBL multilayer build-up approach to
develop an encapsulation methodology for the artificial tissue.
We introduced a phosphorylcholine (PC)-modified sulfated
glycosaminoglycan as the outermost layer in an effort to provide
enhanced biocompatibility of the nanocoating. This method
opens the route toward immunoisolating encapsulation for in
vitro-generated cells that may potentially form the basis for
future treatments for diabetes and other diseases by immune-
protected therapeutic cell transplantation.
Experimental Section
Materials. Tissue culture reagents, including Dulbecco’s modified
Eagle’s medium (DMEM), glutamine, penicillin, streptomycin, phosphate-
buffered saline (PBS), fetal bovine serum, trypsin-ethylenediaminetet-
raacetic acid (EDTA), tolbutamide, and phorbol myristate acetate
(PMA), were from Sigma-Aldrich. Chitosan (low molecular weight,
50-190 kDa, 75% deacetylation; the charge density of chitosan is
directly related to the degree of deacetylation) and alginic acid sodium
salt from crown algae, viscosity of 2% solution at 25 °C, ∼250 cps,
molecular weight, 75-100 kDa, and chondroitin-4-sulfate (20 kDa)
were also from Sigma-Aldrich. Antimouse-MHC Class I antibody
(MCA 2189) was purchased from AbD Serotec (MorphoSys US Inc.).
The fluorescence CellTiter-Blue cell viability assay was purchased from
Promega (Hampshire, U.K.).
Fluorescence Labeling of Chitosan. Chitosan (2 mg) taken from
the 1% (W/V) stock solution was diluted to 1 mL in 10 mM HEPES,
pH 7.4. Alexa Fluor 647 carboxylic acid succinimidyl ester (Invitrogen,
Eugene, U.S.A.; 1 mg) was dissolved in 1 mL dimethylsulfoxide
(Sigma). An aliquot (0.1 mL) of the dye was added to the saccharide
solution and mixed thoroughly overnight at 4 °C on a rocking platform.
The resulting solution was dialyzed for 16 h against 10 mM Tris, pH
7.4, to remove excess dye and stored at 4 °C in the dark until needed
for encapsulation experiments.
Preparation of PC-Modified Chondroitin-4-sulfate. PC-glycer-
aldehyde was prepared by the procedure reported by Miyazawa and
Winnik.23 Hydrazide derivatization of chondroitin-4-sulfate was pre-
pared by the procedure described below. Chondroitin-4-sulfate (100
mg) and carbohydrazide (40 mg) were mixed in formamide (10 mL),
and sonicated for 10 min to dissolve the solids completely. 1-Ethyl-
3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC; Sigma;
90 mg) was then added, and the reaction mixture was stirred at ambient
temperature for 6 h; the reaction product was purified by dialysis
(membrane of MWCO 10000) against 10 mM phosphate buffer, pH
7.4, for 2 days. The PC-modified chondroitin-4-sulfate with a PC
content of one PC per two disaccharide units was synthesized by the
hydrazone formation and reduction amination (see Scheme 1). The
procedure is described below briefly. A solution of PC-glyceraldehyde
(0.10 g) in methanol (2 mL) was added dropwise to the solution of
hydrazide derivatized chondroitin-4-sulfate (the dialyzed solution of
about 15 mL). The reaction mixture was stirred for 30 min at 0 °C and
adjusted the pH to 8.5 by adding aqueous NaOH (0.1 M). The solution
was then added dropwise a solution of sodium cyanoborohydride (0.10
g) in water (1 mL) under stirring at 0 °C and was stirred continuously
overnight at room temperature. The reaction mixture was dialyzed
(membrane of MWCO 10000) against phosphate buffer and then water
for 2 days. The white fiber-like PC-chondroitin-4-sulfate was obtained
by lyophilization (yield ca. 0.15 g). 1H NMR (D2O, δ): 2.90 ppm
(9H, -N+(CH3)3), 3.30 ppm (2H, -CH2-N+-). For detailed NMR
spectra, see Supporting Information.
Maintenance and Preparation of MIN6 Cells. MIN6 -cells
(passage 27-38) were maintained at 37 °C (95% O2/5% CO2) in
DMEM supplemented with 15% fetal calf serum, 2 mM glutamine,
and 100 U/mL penicillin with 0.1 mg/mL streptomycin. The medium
was changed every 3-4 days, and the monolayer cells were trypsinized
(0.1% trypsin, 0.02% EDTA) for experiments when 80-90% confluent.
Preparation of MIN6 Pseudoislets. MIN6 pseudoislets were formed
by culturing MIN6 cells in 90 mm bacterial (uncoated) Petri dishes
under the same conditions as described above for monolayer cells. After
6-8 days of subculturing, each Petri dish contained at least 500 MIN6
pseudoislets with a diameter of about 100 µm (Figure 1). The
pseudoislets formed were sufficiently robust to be handled with glass
or plastic micropipets. During the subculture, some cells die and are
released from the pseudoislets into the culture medium, so the medium
was changed every 3-4 days to remove the suspended dead cells.
Encapsulation of Islet Cells. Low molecular weight chitosan (0.2
g) was dissolved in 1% acetic acid to give a stock solution of 1% (W/
V). An alginate stock solution (1%) was prepared in water. The working
solutions of the polysaccharides (1 mg/mL) were prepared by diluting
the stocks in PBS (pH 7.20), with 2 mM Ca2+ supplemented because
pseudoislet formation was reversible and dependent on extracellular
Ca2+.21 Oppositely charged chitosan and alginate were alternatively
self-assembled into a multilayer film on MIN6 pseudoislets in successive
adsorption steps. After removing the medium from cells, cationic
chitosan (200 µL) was added first to the cells (the cell surface is
negatively charged) to initiate film growth on the cell surfaces. After
a 5 min deposition time, excess unadsorbed chitosan was removed and
cells were washed twice with 0.5 mL PBS, using gravity sedementation
for 1-2 min. Subsequently, the anionic alginate (200 µL) was adsorbed
in the same manner to form a single chitosan/alginate bilayer. This
process was repeated until a desired layering scheme of cells/(chitosan/
alginate)n chitosan was produced, where n represents the number of
bilayers. A protein-repelling PC-chondroitin-4-sulfate was further
Scheme 1. Synthesis of Phosphorylcholine-Modified
Chondroitin-4-sulfate
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deposited as the outermost layer of the coating, making the surface
highly hydrophilic to help reduce nonspecific host responses (e.g.,
fibroid formation) during subsequent transplantation of the capsules.
All encapsulations were performed in a tissue culture hood, and
solutions used for cell encapsulation were filtered through a sterile 0.2
µm membrane filter cartridge. The encapsulated pseudoislets were
visualized using Hitachi H7600 transmission electron microscope
(TEM) after fixing, sectioning and staining.
In Vitro Stability Tests. The stability of pseudoislet cells posten-
capsulation was studied by maintaining the encapsulated cells in culture
medium for 7 days and examining the morphology of pseudoislets with
different layer numbers by microscopy.
Cell Survival in Culture. The long-term cell survival in culture
was tested by a two-color fluorescence viability test involving the use
of propidium iodide (PI) and fluorescein diacetate (FDA).24 The staining
process involved removing medium from cells, adding working
solutions of PI/FDA to cells containing 2 pg of FDA plus 0.6 pg of P1
in 0.2 mL, resuspending the cell suspension, and incubating for 3 min
at room temperature. This was followed by removing the staining
solution and washing cells with 0.5 mL of PBS three times. The cells
were then viewed under a fluorescence microscope with 478-495 nm
and 530-560 nm excitation filters and 510-555 nm and 573-648 nm
emission filters, respectively. This allowed green (alive) and red (dead)
fluorescing cells to be viewed separately. The cell survival test
experiments were carried out after two and five weeks of culturing.
Antibody Exclusion Assay. An antibody exclusion assay was used
to test the permeability of the nanofilm capsules to large molecules.
FITC-labeled antimouse major histocompatibility antigens (MHC) Class
I antibody, with a molecular weight of 150 kDa, which targets MHC
Class I antigens displayed on beta-cell surfaces was used. Antibody-
FITC (1 mg/mL) in PBS was prepared and kept at 4 °C until used.
Pseudoislets (encapsulated) were incubated at 37 °C in the culture
medium (10 mL). To 90 µL of the cell suspension, 10 µL of normal
mouse serum (Invitrogen) was added as the blocking agent, and then
1 µL of antibody-FITC solution was added. The solution was then
placed on an agitator plate for 30 min. The pseudoislets were then rinsed
twice with PBS-Tween (0.5 mL) to remove all unbound dye. Naked
and encapsulated pseudoislet cells were then transferred to a coverslip
for observation with a fluorescence microscope.
Insulin Secretion: Static Incubations. Encapsulated and naked
pseudoislets were aliquoted (in 0.08 mL suspension) in quadruplicate
into 0.5 mL Eppendorf tubes at a density of about 30 islets/tube. After
sedimentation of the cells, the buffer was removed and 0.5 mL solution
added containing (1) 2 mM glucose, (2) 20 mM glucose, (3) 20 mM
glucose plus 500 nM PMA, (4) 20 mM glucose plus 100 µM
tolbutamide, or (5) 20 mM glucose plus 100 µM tolbutamide and 500
nM PMA, all prepared in a bicarbonate-buffered physiological salt,25
supplemented by 2 mM CaCl2 and 0.5 mg/mL bovine serum albumin
(BSA). The cells were then incubated for 30 min at 37 °C (95% O2/
5% CO2). The insulin content of the incubation media (0.1 mL) was
assessed in duplicate by a standard radioimmunoassay.26 Statistical
analysis for the determination of differences in the measured properties
between groups was assessed by Bonferroni’s t-test for multiple
comparisons. Differences were considered to be statistically significant
when the p values were less than 0.05.
Results and Discussion
Selection of Coating Materials. Previous studies have
investigated LBL multilayer coating for living cells using
synthetic polymers like poly(styrene sulfonate) and poly(ally-
laminehydrochloride),apolyanionandapolycation,respectively,7,9
but these were found to be highly cytotoxic,8 and are thus not
generally suitable for the envisaged biomedical applications. We
chose here positively charged chitosan and negatively charged
alginate for the coating materials due to their similarities with
the extracellular matrix, chemical versatility, as well as typically
good biological performance (biocompatibility).27 Chitosan is
a natural, linear cationic polysaccharide comprised of randomly
distributed -(1-4)-linked D-glucosamine and N-acetyl-D-glu-
cosamine. The anionic alginate is also a polysaccharide linear
copolymer with homopolymeric blocks of L-guluronic and
D-mannuronic acid covalently linked in different sequences or
blocks. Both saccharides have been investigated for use in
entrapping cells into beads and other shapes in tissue-engineering
scaffolds which may enhance cell survival and growth.28,29
However, the thickness of the alginate or alginate/chitosan gel
formed typically by interactions between alginate and Ca2+ as
those used in microencapsulation, was usually in the range of
tens to a few hundred µm, which is much thicker compared to
the LBL multilayer films as prepared in this work (in tens nm).
In this work, we have assessed the cytotoxicity of chitosan and
alginate in LBL coatings and the data will be discussed later.
We also tested a PC-modified chondroitin-4-sulfate as the
outermost layer of the coating in order to reduce nonspecific
protein adsorption of the chitosan/alginate nanofilm. The
polymers containing the PC moiety are of particular interest
for biomaterials applications in view of the remarkable protein-
repelling properties and hemocompatibility of the functional
group.30 We prepared PC-modified chondroitin-4-sulfate using
a route whereby PC groups were conjugated via PC-glyceral-
dehyde to a preformed carbohydrazide-derivitized chondroitin-
4-sulfate by reductive amination, which was in a way similar
to that of the preparation of PC-chitosan first proposed by
Miyazawa and Winnik.23
MIN6 Pseudoislet Formation and Nanofilm Coating. Due
to their capacity for propagation in culture in vitro, we used
mouse insulinoma MIN6 cell pseudoislets as an experimental
model for the study of -cell nanoencapsulation methodology.
Previous studies showed that dispersed beta-cells are poorly
responsive to insulin secretagogues due to loss of homotypic
-cell interactions within islets that are crucial for normal
function.20 MIN6 cells grown as adherent monolayers are also
poorly responsive to glucose and other stimuli. However, their
secretory responsiveness is greatly increased when the cells are
grown as three-dimensional islet-like structures (pseudoislets)
in vitro.20,21 The pseudoislets were formed from MIN6 cell
suspensions subcultured in a Petri dish, where the cells did not
adhere to the plastic substrate but developed into three-
dimensional cell clusters (Figure 1). The MIN6 pseudoislets
Figure 1. Illustration showing formation of pseudoislets from MIN6
-cells and the LBL nanofilm encapsulation of the pseudoislets in
multilayer coatings. The right-side image was obtained by coating a
layer of fluorescence-labeled chitosan. The light micrograph (the lower
frame) shows the morphology (∼100 µm in diameter) of a typical
pseudoislet used for nanoencapsulation.
612 Biomacromolecules, Vol. 11, No. 3, 2010 Zhi et al.
reached a diameter of about 100 µm and an appearance similar
to that of primary rodent islets, and contained a cell content of
3000-5000 cells/pseudoislet after 6-8 days of subculturing.20
Pseudoislets were coated with a multilayer of alternating
chitosan and alginate using a LBL process with the first layer
being positively charged chitosan. The deposition of the layer
on cell surfaces was confirmed by depositing a layer of chitosan
labeled with Alexa Fluor 647 (Figure 1). The addition of the
fluorescent chitosan layer to the cell suspension resulted in
strong fluorescence localized mainly on the face of cells at the
pseudoislet periphery, indicating successful coating. Note due
to the nanothickness of each layer, it is impossible for an optical
microscope to resolve whether the islet was fully covered by
the layer or not. By comparing the fluorescence intensity of the
coatings obtained by using fluorescence-labeled chitosan as the
first, third, and fifth layer, respectively, we found that the third
and fifth steps adsorbed the material in greater quantities than
the first step (data not shown). This is likely due to the limited
surface charge on the cell surfaces which resulted in restricted
initial polyelectrolyte coating, but the polysaccharide seeding
layer significantly improved the subsequent layer deposition.
This could be explained that one or both of the polyelectrolytes
diffuse within the initial film during each adsorption cycle,
leading to an exponentially growth of the multilayers.31 The
multilayer deposition on cell surfaces was monitored and
confirmed by electrokinetic zeta-potential measurements (Sup-
porting Information). The average thickness of each dried layer,
according to our previous estimation, was about 1.5 nm.32
The deposition of the polysaccharide nanofilms on the
pseudoislets was further confirmed by TEM imaging of the sec-
tioned encapsulated pseudoislets, as shown in Figure 2. The
images of the pseudoislets showed the coating multilayers were
located continuously around the exterior faces of the pseudo-
islets, and the interior part of the cell plasma membrane was
uncoated, indicating the pseudoislets were coated in bulk.
Meanwhile, the insulin secreting vesicles were aligned along
the plasma membrane ready for exocytosis, and the nuclei
showed no sign of apoptosis, suggesting the beta cells were
healthy and unaffected by the coating. In (a), the cell plasma
membranes at the MIN6 cell-cell interfaces can be seen.
Maintenance of Morphology of the Pseudoislet. Multilayer-
coated pseudoislets exhibited better mechanical robustness than
the naked ones, as indicated by an increase of about 50% in
cell volume after three bilayers were deposited. This can be
explained by the cells becoming mechanically stronger after the
encapsulation, so they cannot be packed as densely as the naked
ones, therefore, occupying more volume. The stability of the
coated pseudoislets was evaluated in vitro by maintaining the
three-dimensional cell capsules in culture medium at 37 °C for
up to 7 days after encapsulated with different numbers of
chitosan/alginate bilayers. Capsule stability was measured by
monitoring the changes in pseudoislet morphology and release
of the dead cells from the formed pseudoislets. As can be seen
in Figure 3, in a coating with one chitosan/alginate bilayer, some
cells were released from the pseudoislets, suggesting that a single
bilayer was not stable enough to maintain the configuration or
mechanical integrity of the pseudoislets, possibly due to
incomplete coverage of the coating on all area of the pseudoislet.
However, cells coated with (chitosan/alginate)2 and (chitosan/
alginate)3 bilayers exhibited a stable coating and spheroid
configuration, with all the cells being retained in the capsule
over 7 days in culture. In subsequent experiments the capsules
were found to be essentially stable for up to five weeks
postencapsulation.
Cytotoxicity of the Coating Materials. The cytotoxicity of
the coating materials in coating was assessed using the CellTiter-
Blue cell viability assay, according to the recommended
Promega protocol. The viability assay is based on the ability of
living cells to convert a redox dye (resazurin) into a fluorescent
end product (resorufin). As shown in Figure 4, coatings of either
a chitosan single layer, or (chitosan/alginate)n multilayers
resulted in no significant deleterious effect on the cell viability
when compared to nonencapsulated control pseudoislets when
the layers were deposited at pH 7.2 (p > 0.05). Exposure of
nonencapsulated control pseudoislets to a medium at pH 5.5
had no detectable effect on cell viability. However, a significant
decrease in the cell viability was observed when coating was
performed at this pH (p < 0.05 for the first coating, and p <
0.01 for successive coatings), and the degree of cytoxicity at
pH5.5 was dependent on the number of layers deposited (Figure
4).
Long-Term Viability of the Encapsulated MIN6 Cells
in Culture. After maintenance in culture medium for various
time periods, the survival of encapsulated cells within three
bilayers was assessed using a two-color fluorescence cell
viability assay with the cell-permeable esterase substrate FDA
and the cell impermeant nucleic acid stain PI (green fluorescence
Figure 2. TEM images of the sectioned encapsulated pseudoislets.
All psedoislets were coated five bilayers comprising (chitosan/
alginate)4 chitosan/PC-chondroitin-4-sulfate. (a,b) Different magnifica-
tions of the nanocoated pseudoislets. (c,d) Cell plasma membranes
inside a pseudoislet were uncoated while the exterior faces of the
pseudoislet were well-coated.
Figure 3. Light microscopy images showing capsule stability in culture
medium as a function of number of bilayers coated.
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indicates the cells being viable, and red indicates the cells dead).
Living cells in a pseudoislet grown in the media for 7 days
was used as the positive control, and dead pseudoislet cells were
obtained by treating the viable cells with 50% PEG200 for 30
min. As shown in Figure 5, most of the cells, particularly those
located near the edge of pseudoislet were viable after two weeks
of culturing. After five weeks, there were a few more dead cells,
but the majority were still viable. Note, due to the 3-D nature
of the pseudoislet, not all of the cells in the pseudoislet could
be visualized at once using a conventional fluorescence mi-
croscopy. The long survival period of the encapsulated cells in
culture suggested again that the pseudoislet was more likely
encapsulated in bulk, but not just only some individual cells
coated. This is because cells coated individually are physically
isolated each other and may rapidly undergo apoptosis and
eventually die due to lack of cell-to-cell interactions. An
unimpaired glucose-dependent insulin secretion and release of
the encapsulated -cells, as described below, further support
this argument.
Exclusion of Large-Molecule Access to the Multilayer-
Coated Cell Surfaces. Effective immunoisolation requires that
the multilayer coating excludes the much larger components of
the immune system, including antibodies and lymphocytes that
would cause rejection and destroy the implant. The ability to
exclude antibodies, which are approximately 150 kDa in size,
is determined by the thickness and density of the coating,
typically achieved via size selection with nanopores of <10 nm.
We used an antibody against MHC Class I antigens to
demonstrate the exclusion of macromolecules. MHC antigens
are a set of plasmalemmal glycoprotein antigens involved in
graft rejection and other immune phenomena, and include two
classes of cell-surface glycoproteins, referred to as class I and
II MHC molecules.33 The antibody used here binds specifically
to the MHA class I expressed on the surface of mouse -cells.
After fluorescence immunoctyochemical staining, fluorescence
microscopy was used to determine the binding of the antibody
to the -cell surface.
We varied the number of layers in the coatings in an effort
to study the effect of film thickness on macromolecule exclusion.
As shown in Figure 6, a naked islet (upper left panel) showed
clear binding of the antibody-FITC probe to the surface of
individual cells within the pseudoislets structures. The image
of a one-bilayer-coated pseudoislet (upper right panel) shows
partial exclusion of the antibody probe, indicating incomplete
film coating, consistent with that observed in stability tests. In
contrast, two- or three-bilayer-coated pseudoislets (middle
Figure 4. Cytotoxicity of the coating materials toward the MIN6 -cells:
effect of coating materials and number of layers on the viability of
the encapsulated pseudoislets, studied at pH 7.2 and 5.5. Chi )
chitosan; Alg ) alginate.
Figure 5. Live/dead MIN6 cells encapsulated within three bilayers of
chitosan/alginate after a 14 (top panel) and a 35 (middle panel) day
postencapsulation maintained in tissue culture. The lower panels show
the controls of the viable and dead cells (nonencapsulated). Green:
viable; red: nonviable. CS-PC ) phosphorylcholine-substituted chon-
droitin-4-sulfate.
Figure 6. Fluorescence images of MIN6 -cells showing the penetra-
tion or exclusion of anti-MHC-FITC by the chitosan/alginate and
chitosan/alginate/phosphorylcholine-substituted chondroitin-4-sulfate
multilayers. The size of each pseudoislet is around 100 µm.
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panels) showed clear exclusion of the antibody probe from
access to the cell surface. However, low levels of fluorescence
were detected around the periphery of the capsules surrounding
the clusters, suggesting some nonspecific antibody adsorption
on the nanofilm that may potentially induce fibrotic overgrowth
on the capsule. To minimize the nonspecific binding of the
antibody, we tested further deposition of a protein-repelling
biopolymer PC-chondroitin-4-sulfate on the top of (chitosan/
alginate)2chitosan multilayers. As shown in Figure 6 (the lower
panels), deposition of one or two layers of chondroitin-4-sulfate-
PC reduced strongly the antibody adsorption on the surfaces.
Insulin Secretion from Encapsulated Pseudoislets. We
investigated whether the nanofilm coatings affected the function
of the beta-cells and whether the nanocoating permits the pas-
sage of small molecules like insulin (MW 5.7 kDa), glucose
and oxygen through the coating film. We measured the release
of insulin from coated and naked control pseudoislets in response
to glucose (2 vs 20 mM) and a non-nutrient stimulator of insulin
secretion, the protein kinase C activator, PMA (500 nM).34 As
shown in Figure 7, the basal rate of insulin release into the
medium at a substimulatory glucose concentration (2 mM) was
similar for both naked and encapsulated cells. Note the original
basal concentration in the medium was 0.75 ng/mL after a
dilution factor of 1 to 5. Increasing the glucose concentration
to a maximum stimulatory concentration (20 mM), significantly
enhanced insulin secretion from both control and encapsulated
pseudoislets (p < 0.01), and this glucose-induced insulin
secretory response was further enhanced by the presence of
PMA (500 nM).
Under all conditions tested, the overall mass of insulin
released from encapsulated cells was ∼20-30% less than from
nonencapsulated control cells. This could not be attributed to
differences in insulin content, because our direct measurements
of insulin in cell extracts found no significant differences
between control and encapsulated cells, consistent with the
viability of the encapsulated pseudoislet cells (Figures 4 and
5). We therefore considered whether the reduced rate of insulin
release from encapsulated cells was due to impaired -cell
function, or to the mass diffusion limitations of the nanofilm.
When the data for insulin secretion (Figure 7) were expressed
relative to the appropriate basal rate of secretion (2 mM glucose)
the magnitude of the secretory responses induced by glucose
and PMA were very similar between control and encapsulated
pseudoislets (controls: 20 mM glucose 151 ( 18% basal, mean
( SEM, n ) 4; 20 mM glucose plus 500 nM PMA, 229 (
32% basal; encapsulated: 20 mM glucose 155 ( 18% basal;
20 mM glucose plus 500 nM PMA, 226 ( 37% basal). These
observations suggest that the encapsulation process did not
impair the ability of the cells to respond appropriately to glucose
nor influence the enhancement of glucose-induced insulin
secretion by a non-nutrient secretagogue, such as PMA. This
conclusion was confirmed in further experiments in which we
used the sulphonylurea drug, tolbutamide, to induce insulin
secretion. The sulphonylureas bypass the glucose-regulated
stimulus-response pathway by interacting directly with ATP-
sensitive K+ (KATP) channels in the -cell plasma membrane to
induce depolarization, with the consequent influx of extracellular
Ca2+ and initiation of the exocytotic release of insulin.35
Although its mode of action ensures that tolbutamide activates
all the -cells within the pseudoislets, the secretory responses
to tolbutamide (100 µM) were similar to those induced by
glucose and PMA, with encapsulated cells releasing less insulin
than control cells (∼20%). However, the magnitude of the
tolbutamide-induced response over basal was similar between
encapsulated and control cells, consistent with the encapsulation
process imposing a mass transport limitation for secreted insulin
diffusing through the standard three-layer nanofilm (controls:
100 µM tolbutamide, 161 ( 23% basal, mean ( SEM, n ) 4;
100 µM tolbutamide plus 500 nM PMA, 265 ( 12% basal;
encapsulated: 100 µM tolbutamide, 183 ( 19% basal; 100 µM
tolbutamide plus 500 nM PMA, 248 ( 12% basal). Furthermore,
increasing the encapsulation process to five bilayers was found
to not further significantly impede insulin release into the
medium, while pseudoislets encapsulated with only one bilayer
showed insulin secretory responses similar to the nonencapsu-
lated cells (data not shown).
In summary, our measurements of insulin secretion from
encapsulated pseudoislets demonstrate that the encapsulation
methodology did not compromise the ability of the MIN6 cells
to recognize and respond to changes in the extracellular
concentration of nutrient stimuli, such as glucose; to non-nutrient
stimuli, such as PMA or to depolarizing pharmacological
agonists such as tolbutamide. These observations confirm the
metabolic and secretory viability of the encapsulated -cells in
pseudoislets and suggest that this method of encapsulation is
compatible for maintaining the secretory function of transplanted
islets.
Conclusions
By using pseudoislets formed from MIN6 -cells as an
experimental model, we have demonstrated the feasibility of a
polysaccharide nanoencapsulation methodology for islet-like
-cell spheroids. The preservation of cellular metabolism of the
cells postencapsulation and efficient exclusion of antibodies to
the capsule was demonstrated and suggested this nanofilm
encapsulation technique has the characteristics required for
improved transplantation of insulin-producing cells. A PC-
modified chondroitin-4-sulfate layer was found to be an effective
way of developing biocompatible surface coatings of controlled
protein adsorption properties. This work establishes the basis
for a versatile approach for encapsulating cell clusters formed
from isolated single cell suspensions. While the MIN6 cells used
in this study may not match exactly the insulin secretory kinetics
of normal human or animal islets, therefore, not necessarily
being compatible with the transplantation models, the methodol-
ogy using self-organized pseudoislets is generic and has
important implications for use in a variety of in vitro-generated
Figure 7. Insulin release of the control (naked) and encapsulated
MIN6 pseudoislets in response to nutrient and non-nutrient stimuli.
Insulin release into the incubation medium was normalized against
basal (2 mM glucose) secretion from control pseudoislets. Each
observation used about 30 pseudoislets, and bars show means (
SEM values for four independent observations, each of which was
assayed in duplicate for the insulin content.
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cellular therapeutics where technological and immunological
barriers to cell transplantation exist. In future research, it will
be necessary to further optimize the nanocoatings using an in
vivo transplantation animal model with a view to obtaining
significantly improved long-term survival of the transplanted
cells.
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